Sugi Predict

Sugi Predict / Compounds / SCHEMBL16660830

SCHEMBL16660830

SCHEMBL16660830

FC(F)(F)c1nnc(-c2ccc(Br)cc2)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 2/20 0.47
▸ MAPK13 O15264 4/20 0.37
▸ GCGR P47871 4/20 0.37
▸ MAPK12 P53778 4/20 0.37
▸ MAPK11 Q15759 4/20 0.37
▸ MAPK14 Q16539 4/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ ATM Q13315 1/20 0.35
▸ TNKS O95271 3/20 0.35
▸ TNKS2 Q9H2K2 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ CYP1A1 P04798 1/20 0.35
▸ CYP1B1 Q16678 1/20 0.35
▸ NR1I3 Q14994 1/20 0.35
▸ DGAT1 O75907 1/20 0.34
▸ NR1H2 P55055 1/20 0.34
▸ NR1H3 Q13133 1/20 0.34
▸ IDO1 P14902 1/20 0.33
▸ PTGES O14684 1/20 0.33
▸ RAD51 Q06609 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16599396 0.81 KIF11 (0.44) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL38659101 0.80 KIF11 (0.47) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL20401786 0.80 MAPK13 (0.46) TRPV1MAPK13GCGRMAPK12MAPK11
SCHEMBL16660964 0.76 SPR (0.40) TRPV1
SCHEMBL1505609 0.76 CYP11B2 (0.44) TRPV1
SCHEMBL16660942 0.73 NPC1 (0.44) KDM4E
SCHEMBL16661157 0.72 ALDH1A1 (0.58) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL31429116 0.71 MAPK13 (0.40) TRPV1MAPK13GCGRMAPK12MAPK11
SCHEMBL823787 0.71 MAPK13 (0.43) TRPV1MAPK13GCGRMAPK12MAPK11
SCHEMBL5219548 0.71 DGAT1 (0.41) TRPV1MAPK13GCGRMAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 — — WO disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
EP-4251625-A1 TRICYCLIC COMPOUNDS Aligos Therapeutics, Inc. (US) 2023-10-04 — — EP disclosed
WO-2022115384-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2022-06-02 — — WO disclosed
WO-2022115384-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2022-06-02 — — WO disclosed
US-20220169650-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-06-02 — — US disclosed
WO-2022011338-A2 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2022-01-13 — — WO disclosed
US-10308636-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-04 — — US disclosed
EP-2862856-B1 IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2018-08-01 — — EP disclosed
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-23 — — US disclosed
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-23 — — US disclosed
US-9546155-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-17 — — US disclosed
US-9546155-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-17 — — US disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 — — US disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 — — US disclosed
EP-2862856-A1 AROMATIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2015-04-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND GPR119, NR0B1, BET1 TRPV1 1867/4885MAPK13 1701/4885GCGR 67/4885
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, MAPKAPK2, MAP3K20 TRPV1 3015/4885MAPK13 91/4885GCGR 3101/4885
US-20220169650-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL TRPV1 204/4885MAPK13 1830/4885GCGR 1314/4885
US-10308636-B2 Aromatic heterocyclic compound GPR119, NR0B1, BET1 TRPV1 1867/4885MAPK13 1701/4885GCGR 67/4885
US-11820773-B2 Tricyclic compounds SLC10A1, PKD1, CEL TRPV1 204/4885MAPK13 1830/4885GCGR 1314/4885
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND GPR119, NR0B1, BET1 TRPV1 1867/4885MAPK13 1701/4885GCGR 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.